GRIFOLS S A/S (NASDAQ:GRFS) Lifted to Sell at BidaskClub

GRIFOLS S A/S (NASDAQ:GRFS) was upgraded by equities research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Tuesday, BidAskClub reports.

Separately, Zacks Investment Research lowered GRIFOLS S A/S from a “hold” rating to a “sell” rating in a research report on Monday, April 1st. Three investment analysts have rated the stock with a sell rating and four have issued a hold rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $19.00.

Shares of GRFS opened at $19.28 on Tuesday. The company has a market capitalization of $13.42 billion, a PE ratio of 16.97, a PEG ratio of 1.17 and a beta of 1.04. The company has a quick ratio of 1.13, a current ratio of 2.87 and a debt-to-equity ratio of 1.41. GRIFOLS S A/S has a 52 week low of $17.42 and a 52 week high of $24.97.



GRIFOLS S A/S (NASDAQ:GRFS) last issued its earnings results on Tuesday, May 7th. The biotechnology company reported $0.25 EPS for the quarter, hitting the consensus estimate of $0.25. The company had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. GRIFOLS S A/S had a return on equity of 15.49% and a net margin of 12.35%. Equities analysts expect that GRIFOLS S A/S will post 1.27 earnings per share for the current year.

Several institutional investors and hedge funds have recently modified their holdings of GRFS. AKO Capital LLP boosted its position in GRIFOLS S A/S by 24.7% during the 4th quarter. AKO Capital LLP now owns 12,283,473 shares of the biotechnology company’s stock valued at $225,525,000 after purchasing an additional 2,436,502 shares during the period. First Trust Advisors LP boosted its position in GRIFOLS S A/S by 9.7% during the 1st quarter. First Trust Advisors LP now owns 5,125,719 shares of the biotechnology company’s stock valued at $103,078,000 after purchasing an additional 453,032 shares during the period. Two Sigma Advisers LP boosted its position in GRIFOLS S A/S by 502.7% during the 4th quarter. Two Sigma Advisers LP now owns 134,400 shares of the biotechnology company’s stock valued at $2,468,000 after purchasing an additional 112,100 shares during the period. Bank of America Corp DE boosted its position in GRIFOLS S A/S by 1.2% during the 4th quarter. Bank of America Corp DE now owns 1,443,713 shares of the biotechnology company’s stock valued at $26,506,000 after purchasing an additional 16,818 shares during the period. Finally, CIBC Asset Management Inc boosted its position in GRIFOLS S A/S by 79.6% during the 1st quarter. CIBC Asset Management Inc now owns 210,981 shares of the biotechnology company’s stock valued at $4,243,000 after purchasing an additional 93,510 shares during the period. Institutional investors own 19.02% of the company’s stock.

About GRIFOLS S A/S

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.

Read More: How do buyers and sellers choose a strike price?

Analyst Recommendations for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.